Renal cell carcinoma in the coming era of robotic technology
Authors:
Ivan Kolombo 1; Jiří Poněšický 1; Michal Toběrný 1; Radko Kříž 2; Iva Zemanová 3; Jiří Weichet 2; Josef Vymazal 2; Stanislav Černohorský 1; Milan Bartůněk 1
Authors place of work:
Centrum robotické chirurgie a urologie Nemocnice Na Homolce, Praha
1; Radiodiagnostické oddělení Nemocnice Na Homolce, Praha
2; Patologicko-anatomické oddělení Nemocnice Na Homolce, Praha
3
Published in the journal:
Čas. Lék. čes. 2011; 150: 215-222
Category:
Review Article
Summary
Renal cell carcinoma is the most malignant urological tumour and the incidence in the Czech Republic is currently highest in the world. Kidney cancer is associated with seven different genes and is characterized nowadays as metabolic disease. Authors present some current facts about advances in diagnosis and new treatmen methods. Different findings required individual approach. Diagnosis improved with more sophisticated ultrasonography, computed tomography, magnetic resonance imaging and positron emission tomography etc. Apart from standard surgery new alternative methods of minimally invasive procedures also assert (laparoscopy, robotic surgery, radiofrequency ablation, kryoablation) and are incorporated in current complex treatment strategies. Systemic therapy with new targeted antiangiogenics drugs is a new standard of treatment for metastatic kidney cancer. Complex care with integration of local treatment (surgery, radiotherapy, selective embolization, radiosurgery, cementoplasty, vetrebroplasty etc.) and systemic medication with best supportive care is optimal for a metastatic kidney cancer. More accurate diagnostic methods and complex interdisciplinary approach with integration of systemic therapy with new targeted drugs and new minimally invasive procedures represent new possibilities for patients with kidney cancer.
Key words:
kidney cancer, laparoscopy, robotic surgery, vertebroplasty, cementoplasty, selective embolization, metastasectomy, radiofrequency ablation, targeted therapy.
Zdroje
1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita [2005] (cit. 18. 2. 2011). Dostupný z www: http: //www.svod.cz. Verze 7.0 [2007].
2. Novotvary v České republice. Ústav zdravotnických informací a statistiky ČR 2009 (cit. 18. 2. 2011) Dostupné z: ÚZIS ČR (Institute of health information and statistics of the Czech republic – IHIS CR) http://www.svod.cz.
3. GLOBOCAN 2002, Cancer incidence, Mortality and revalence Worldwide. IARC Cancer Base, Lyon IARC 2002.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2006. CA Cancer J Clin 2006; 56: 106–130.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74–108.
6. Abou El Fettouh HI, Cherullo EE, El-Jack M, et al. Sporadic renal cel carcinoma in young adults: presentation, treatment, and outcome. Urology 2002; 60: 806–810.
7. Kolombo I, Poněšický J, Poršová M, et al. Pokročilý karcinom ledviny – současné trendy terapie (1. část). Urologie pro Praxi 2009; 10: 182–189.
8. Kawaciuk I. Epidemiologie karcinomu ledviny, Urologie pro praxi 2005; 6: 248–252.
9. Ljunberg B, Hanbury DC, Kuczyk MA, Mersenburger AS, Mulders PFA, Patard J-J, Sinescu IC. EAU Guidelines on Renal Cell Carcinoma, EAU, Update 2009, www.uroweb.org.
10. Gudbjartsson T, Jonasdottir TJ, Thoroddsen A, et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 2002; 100: 476–479.
11. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Uro 2010; 7: 277–285.
12. Zbar B, Klausner R, Linehan WM. Studying cancer families to identify kidney cancer genes. Annu Rev Med. 2003; 54: 217–233.
13. Brugarolas J. Renal-cell carcinoma – molecular pathways and therapies. NEJM 2007; 356: 185–187.
14. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006; 12: 122–127.
15. Babjuk M, Matoušková M, Fínek J, et al. Zhoubné nádory ledvinového parenchymu dospělého věku; 37–43. In: Konsenzuální doporučené postupy u uroloonkologii. Praha: Galén 2009.
16. Kolombo I, Hanuš T, Odrážka K, et al. Karcinom ledviny. Praha: Mladá Fronta – Aeskulap 2010; 1–279.
17. Michal M, Hes O, Mukenšnabl P. Nádory ledvin dospělého věku. 1. vyd. Plzeň: Euroverlag 2000.
18. Sobin LH, Gospodariwicz M, Wittekind C (eds). TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. London: Wiley-Blackwell 2009: 255–257.
19. Kavoussi LR, Levine SR, Kadmon D, Fair WR. Regression of metastatic renal cell carcinoma: A case report and literature review. J Urol 1986; 135: 1005–1007.
20. Thoroddsen A, Gudbjartsson T, Geirsson G, et al. Spontaneous regression of pleural metastases after nephrectomy for renal cell carcinoma. Scand J Urol Nephrol 2002; 36: 396–398.
21. Adam Z, Vorlíček J, Vaníček J, et al. Diagnostické a léčebné postupy u maligních chorob. Praha: Grada Publishing 2003
22. Weichet J, Vymazal J. Zobrazovací metody (sono, CT, MRI) In: Kolombo I, Hanuš T, Odrážka K, et al. Karcinom ledviny. Praha: Mladá Fronta – Aeskulap 2010; 83–93.
23. Klener P, Abrahámová J. Nádory ledvin. In: Klener P. Klinická onkologie. Praha: Galén a Karolinum 2002; 435–442.
24. Kolombo I, Kolombová J, Dvořáček J, Hanuš T, et al. Skeletální postižení v uroonkologii. Praha: Galén 2005.
24. Bělohlávek O. Nukleárně medicínské zobrazovací metody. In: Kolombo I, Hanuš T, Odrážka K et al. Karcinom ledviny. Mladá Fronta – Aeskulap Praha 2010; 94–103.
26. Hora M. Nádory ledvin. Urologie pro Praxi 2005; 1: 28–30.
27. Rovný A, Filipenský P, Šabacký I, et al. Nádory ledvin. In: Adam Z, Vorlíček J. Speciální onkologie. Brno: Masarykova Univerzita 2002; 139–149.
28. Hanuš T. Surgical management of renal tumours with vena cava involvement: is it a job of urologists? Ces Urol 2009; 13: 25–28.
29. Kolombo I, Kolombová J, Beňo P, Toběrný M, et al. Mezioborová spolupráce v urologii. Urologie pro Praxi 2007; 8: 262–267.
30. Morávek P. Nádory ledvin a horních močových cest. Chirurgická terapie. In: Dvořáček J, Babjuk M, et al. Onkourologie. Praha: Galén a Karolinum 2005; 44–56.
31. Kolombo I, Poněšický J, Poršová M, et al. Pokročilý karcinom ledviny – současné trendy terapie (2. část). Urologie pro Praxi 2009; 10: 218–230.
32. Mejean A, Vogt B, Quazza JE, Chretien Y, Dufour B. Mortality and morbidity after nephrectomy for renal cell carcinoma using a transperitoneal anterior subcostal incision. Eur Urol 1999; 36: 298–302.
33. Eret V, Hora M, Ferda J, Chudáček Z, Hes O, Ürge T, Klečka J. Nejnovější metodiky v chirurgické léčbě nádorů ledvin. Ces Urol 2009; 13: 24–25.
34. Kolombo I, Kříž R, Janoušková L, et al. Selective embolization and radiofrequency ablation of renal mass in polymorbid and elderly patients – our experience. Eur Urol Meetings 2007; Abstracts of the EAU 7th Central European Meeting 26–27 October 2007, Zagreb, Croatia, Vol 2, Issue 7, Abstract 26.
35. Barocas DA, Chang SS. The role of cytoreductive nephrectomy in the era of targeted therapy. AUA News 2008; 13: 1–6.
36. Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 2007; 177: 1978–1984.
37. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal cell cancer. N Engl J Med 2001; 345: 1655–1659.
38. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon α-based immunotherapy compared with interferon α alone for metastatic renal cell carcinoma: a randomized trial. Lancet 2001; 358: 966–970.
39. Russo P, Synder M, Vickers A, et al. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. Scientific World Journal 2007; 7: 768.
40. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007; 356: 115–124.
41. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 2007; 25(Suppl): abstract 5024.
42. Margulis V, Martin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurent renal cell carcinoma. J Urol 2008; 180: 94–98.
43. Gronka L, Poršová M, Kolombo I, et al. Karcinom ledviny současné trendy. Urologie pro Praxi 2008; 9: 120–127.
44. Hartmann I, Študent V, Grepl M, et al. Laparoskopická nefrektomie – zlatý standard? Ces Urol 2008; 12: 116 – abstract 58.
45. Hemal AK, Kumar A, Kumar R, et al. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol 2007; 177: 862–866.
46. Kaplan O, Köhler O, Kočárek J, et al. Roboticky asistované resekce tumoru ledvin – první zkušenosti. Ces Urol 2008; 12: 118 – abstract 62.
47. Kolombo I, Toběrný M, Černohorský S, et al. Laparoskopické roboticky asistované operace ledvin. Endoskopie 2008; 17: 35–42.
48. Rogers C, Patard J. Robotic partial nephrectomy is better than open partial nephrectomy. Eur Urol 2009; 56: 568–570.
49. Benway BM, Bhayani SB. Robot-assisted partial nephrectomy: evolution and recent advances. Curr Opin Urol 2010; 20: 119–124.
50. Benway BM, Bhayani SB, Rogers CG, et al. Robot-assisted partial nephrectomy versus laparoscopic partial nephrectomy for renal tumors: A multi-institutional analysis of perioperative outcomes. J Urol 2009; 182: 866–872.
51. Guillonneau B, Jayet C, Tewari A, Vallancien G. Robot assisted laparoscopic nephrectomy. J Urol 2001; 166: 200–201.
52. Kolombo I, Toběrný M, Černohorský S, et al. Robotická chirurgie v urologii. NEUMM 2008; 2: 84–93
53. Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors – is there a difference in mortality and cardiovascular outcomes? J Urol 2009; 181: 55–61, discussion 61–62.
54. McKiernan J, Simmons R, Katz J, et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 2002; 59: 816.
55. Miller DC, Schonlau M, Litwin MS, et al. Urologic Diseases in America Project. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 2008; 112: 511–520.
56. Thompson RH, Boorjian SA, Lohse CM, et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 2008; 179: 468–471, discussion 472–473.
57. Andonian S, Adebayo A, Okeke Z, Lee BR. Habib laparoscopic bipolar radiofrequency device: a novel way of creating an avascular resection margin in laparoscopic partial nephrectomy. J Laparoendo Adv Surg Tech 2008; 18: 853–856.
58. Navrátil P, Pacovský J, Všetička J, Podhola M, Matějková M, Zachoval R. Resekce ledvin radiofrekvenčním nožem – radikalita a destrukce funkčního parenchymu. Ces Urol 2008; 12: 120 – abstract 64.
59. Gill IS, Canes D, Aron M, et al. Single port transumbilical (E‑NOTES) donor nephrectomy. J Urol 2008; 180: 637–641.
60. Kaouk JH, Goel RK. Single-port laparoscopic and robotic partial nephrectomy. Eur Urol 2009; 55: 1163–1170
61. Raman JD, Bensalah K, Bagrodia A, et al. Laboratory and clinical development of single keyhole umbilical nephrectomy. Urology 2007; 70: 1039–1042.
62. Mahnken AH, Rohde D, Brkovic D, et al. Percutaneous radiofrequency ablation of renal cell carcinoma: preliminary results. Acta Radiol 2005; 46: 208–214.
63. Kolombo I, Chrobok J, Poněšický J, et al. Our first experience with replacement for vertebral body by Synex® device for spine metastatic disease of urooncological patients. Eur Urol Meetings 2007; Abstracts of the EAU 7th Central European Meeting 26–27 October 2007, Zagreb, Croatia, Vol 2, Issue 7, Abstract 98.
64. Rubinsky B. Irreversible Electroporation: A New Ablation Modality – Clinical Implications. Technology in Cancer Research and Treatment 2007; 6: 37–47.
65. Zachoval R, Urban M, Heráček J, et al. Současný pohled na metastazující karcinom ledviny z hlediska přežití v závislosti na druhu terapie. Urologie pro Praxi 2003; 5: 190–192.
66. Kolombo I, Hanuš T, Kolombová J. Možnosti laboratorní diagnostiky metabolických změn skeletu. Čas Lék čes 2005; 144: 162–167.
67. Jarolím J, Abrahámová, J, Buncová M, et al. Kostní metastázy. Program urologie a onkologie Elektronické Univerzity. 2007 www.euni.cz.
68. Kolombo I, Kolombová J, Vlásek T. Místo bisfosfonátů při skeletálním postižení v uroonkologii, Urologie pro Praxi, 2006; 5: 228–242.
69. Thompson Coon JS, Liu Z, Hoye M, et al. Sunitinib and bevacuzimab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer 2009; 101: 238–243.
70. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271–2281.
71. Melichar B, Koralewski P, Ravaud A, et al. First-line bevacizumab combined with reduced dose interferon-alpha 2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008; 19: 1470–1476.
72. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372: 449–456.
73. Odrážka K, Kolombo I, Hanuš T. Algorytmus léčby. In: Kolombo I, Hanuš T, Odrážka K et al: Karcinom ledviny. Praha: Mladá Fronta – Aeskulap 2010, 242–247.
74. Petruželka L. Nové možnosti systémové léčby karcinomu ledviny. Remedia 2008; 18: 35–45.
75. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2010; 28: 1061–1068.
76. Linehan WM, Bratslavsky G, Pinto PA, et al. Molecular diagnosis and therapy of kidney cancer. Ann Rev Med 2010; 61: 329–343.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Early repolarisation syndrome and idiopathic ventricular fibrillation
- Temporal lobe epilepsy in adults and possibilities of neurosurgical treatment: the role of magnetic resonance
- Nonconvulsive status epilepticus
- Measurement of exhaled nitric oxide in the diagnosis of asthma